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Abstract: To ensure their survival, a number of bacterial and plant species have evolved a 
common  strategy  to  capture  energy  from  other  biological  systems.  Being  imperfect 
pathogens,  organisms  synthesizing  multi-subunit  AB  toxins  are  responsible  for  the 
mortality of millions of people and animals annually. Vaccination against these organisms 
and  their  toxins  has  proved  rather  ineffective  in  providing  long-term  protection  from 
disease. In response to the debilitating effects of AB toxins on epithelial cells of the digestive 
mucosa,  mechanisms  underlying  toxin  immunomodulation  of  immune  responses  have 
become the focus of increasing experimentation. The results of these studies reveal that AB 
toxins  may  have  a  beneficial  application  as  adjuvants  for  the  enhancement  of  immune 
protection against infection and autoimmunity. Here, we examine similarities and differences 
in the structure and function of bacterial and plant AB toxins that underlie their toxicity and 
their exceptional properties as immunomodulators for stimulating immune responses against 
infectious disease and for immune suppression of organ-specific autoimmunity. 
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1. Introduction  
Historically, AB subunit toxins synthesized by a variety of bacterial pathogens and plants have 
occupied a loathsome place in man’s lexicon. They have traditionally been and still remain the subject 
of intense research in an ongoing effort to overcome their capacity to degrade the intestinal epithelium, 
resulting in severe diarrhea and the untimely death of millions of children and adults annually, largely 
throughout the developing world. More recently however, there has emerged a more optimistic and 
encouraging story suggesting that AB toxins may soon become one of man’s best allies in the battle 
against infection and autoimmunity. During the past two decades, AB toxins have shown increasing 
promise as effective, safe, and durable adjuvants for the stimulation of immunity or alternatively, the 
suppression  of  autoimmunity.  In  this  review,  we  examine  the  similarities  and  differences  in  the 
structure and function of bacterial and plant AB toxins in anticipation of the scientific challenges and 
strategic priorities required for modern vaccine development (Table 1). 
Table 1. Summary of Plant and Bacterial AB Toxin Structure and Function. 
  A Subunit(s)  B Subunit(s)  Enzymatic Activity  Target  Receptor(s) 
Cholera toxin 
A1: 22 kDa  (× 5) 10.6 kDa  ADP-ribosyl transferase  Adenylate cyclase  GM1 ganglioside 
A2: 5 kDa      G-protein (Gsα)   
E. coli (LT) 
A1: 22 kDa  (× 5) 11.6 kDa  ADP-ribosyl transferase  G-protein (Gsα)  GM1 ganglioside 
A2: 5 kDa        Asialoganglioside 
Shiga toxin 
A1: 28 kDa  (× 5) 7.7 kDa  N-glycosylase  rRNA (28S)  Gb3 glycolipid 
A2: 4 kDa    (Cleaves adenine 4324)     
Pertussis toxin 
S1: 28 kDa  S2: 23 kDa  ADP-ribosyl transferase  G-protein (Gsα)  GD1a ganglioside 
  S3: 22 kDa       
  S4: (× 2) 11.7 kDa       
  S5: 9.3 kDa       
Anthrax 
(LF): 90 kDa  (PA): (× 7) 83 kDa  Zn metalloprotease  MAPKK  ANTXR 1 
(EF): 89 kDa    Adenylate cyclase  Protein kinases  ANTXR 2 
Ricin 
30 kDa  29 kDa  N-glycosylase  rRNA (28S)  Glycoprotein 
    (Cleaves adenine 4324)    Glycolipid 
2. Cholera Toxin 
2.1. Structure, Pathogenesis and Biological Function 
Cholera  enterotoxin  (CT)  is  an  oligomeric  protein  produced  in  nature  by  the  Gram  negative 
bacterium Vibrio cholerae. Cholera toxin causes a high volume of secretory diarrhea initiated in the 
upper part of the small intestine. Initial studies suggested that the cholera toxin consisted of a single 
protein subunit of 84 kDa [1]. However, SDS-PAGE analysis showed CT consisted of a single large A 
subunit (CTA) of approximately 27 kDa and a pentameric B subunit (CTB) with  an approximate 
monomer molecular weight (MW) of 10.6 kDa [2]. The CTA subunit was further shown to be divided 
into  CTA1  and  CTA2  subunits  linked  by  a  disulfide  bond.  The  CTA1  subunit  was  found  to  be 
responsible for CT toxicity [3]. The assembly of CT structure revealed that the toxic CTA1 subunit 
contained ADP-ribosylating activity, while the helical CTA2 fragment was found to be responsible for Toxins 2010, 2  
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embedding the CTA1 subunit into the center of the doughnut shaped CTB pentameric oligomer [4]. In 
addition, the CTB subunit, held together by hydrogen bonds and salt bridges, was shown to bind to 
ganglioside GM1[Gal(β1-3)galNac(β1-4)(NeuA-c(α2-3)Gal(β14)Glc]→ceramide [5], an anchor molecule 
embedded in the mammalian epidermal cell membrane [6,7] (Figure 1). Cholera toxin was shown to 
bind and infect a variety of somatic cells in vivo, especially in intestinal epithelial cells, through high 
affinity  binding  of  the  toxin  to  its  cell  surface  receptor  GM1  ganglioside  [7–10].  However,  only 
epidermal cells in the Go/G1 phase of the cell cycle were shown to both bind and internalize CT. 
Figure 1. Crystal structure of cholera toxin. The heterodimeric CTA protein subunit (blue) 
is composed of two polypeptide chains, CTA1 (22 kDa) and CTA2 (5 kDa), linked by a 
single  disulfide  bond.  The  enzymatically  active  CTA1  peptide  is  the  (toxic)  
mono-ADP-ribosyltransferase  subunit,  while  the  CTA2  helical  peptide  links  the  CTA1 
subunit  to  the  pentameric  CTB  subunits.  The  cholera  toxin  B  subunit  (10.6  kDa)  is 
composed of five identical polypeptide subunit chains (yellow, purple, red, orange, and 
turquoise), each with membrane receptor GM1ganglioside binding capacity. 
 
Cholera toxin resembles another diarrhea causing bacterial toxin, the heat labile enterotoxin (LT) 
synthesized by the bacterial pathogen, enterotoxigenic Escherichia coli (ETEC). Both CT and LT 
share  approximately  80%  amino  acid  sequence  homology  and  possess  similar  three-dimensional 
molecular structures with minor differences in configuration and function [4] (Figure 2). Differences 
between  CT  and  LT  involve  proteolytic  cleavage  of  the  CTA  subunit  into  CTA1  and  CTA2,  in 
comparison  with  LT,  which  is  cleaved  into  LTA1  and  LTA2  subunits  by  internal  trypsinization. 
Moreover, CT was found to be encoded in a prophage whereas LT is encoded in a bacterial plasmid. 
Heat sensitive LT can bind to GM1 and GD1 ganglioside, as well as several additional intestinal 
glycoproteins, while CT binds preferentially and almost exclusively to the GM1 ganglioside [4,11]. 
Cholera toxin secretion in bacteria involves transport across the outer membrane through a CT 
secretion  system  known  as  the  extracellular  protein  secretion  system  (Eps)  [12].  The  energy  for 
secretion  is  provided  by  EpsE,  a  cytoplasmic  ATPase  that  forms  a  complex  with  other  secretory 
proteins  to  transfer  CT  across  the  periplasmic  compartment  [13].  This  transfer  is  believed  to  be 
facilitated by the outer membrane component of the Eps, EpsD, which induces opening of the channel Toxins 2010, 2  
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and subsequent secretion [14]. This protein transfer system moves CT from the periplasm, where its 
subunits are assembled, across the membrane, and into the extracellular environment [15,16]. In order 
to mediate its toxic activity, CT binds with high affinity to the GM1 ganglioside in lipid rafts on the 
epidermal cell surface of the lumen of the small intestine. The high binding affinity of CTB to the 
ganglioside GM1 is due to the contribution of a single amino acid (Gly33) on the neighboring CTB 
monomer  to  the  GM1  binding  site  on  an  adjacent  CTB  monomer  [17].  Subsequently,  the  crystal 
structure  of  CT  revealed  that  Tyr12  on  the  CTB  monomer,  along  with  Gly33  and  Trp88  on  the 
adjacent monomer, are critical for CT-GM1 interaction [18]. 
Figure  2.  Pictorial  representation  of  structural  and  amino  acid  sequence  homologies 
among bacterial and  plant AB  enterotoxins. (A) The  top panel represents  the  catalytic 
(toxic)  A  subunit  proteins;  (B)  The  bottom  panel  represents  the  membrane  binding  B 
subunit  proteins.  Approximate  values  for  amino  acid  sequence  homologies  observed 
among the AB subunits depicted from different enterotoxins are provided as percentages. 
Enterotoxin  subunits  with  no  arrows  between  them  share  little  to  no  amino  acid  or 
structural homologies [19]. 
 
The binding of CT via its CTB subunits to GM1 permits toxin endocytosis through caveolin-coated 
and clathrin-coated vesicles [20]. In addition, CT has been shown to enter cells through both an Arf6 
dependent pathway and a non-Arf6 dependent pathway, which still remains unidentified. Interestingly, 
blocking all the known endocytic pathways does not appear to alter the toxicity of CT within the cell 
[21]. The toxin is transported not only to endosomes, but also to the endoplasmic reticulum (ER) via 
Golgi retrograde transport mechanisms [22]. An endoplasmic reticulum retention motif (KDEL) is 
located near the C terminus of the CTA chain. This motif allows the toxin to interact with the KDEL 
receptor, which permits the recycling of ER components from the trans-Golgi network (TGN), back to 
the ER [23]. Endocytosis of the toxin results in CTA1 subunit induction of adenylate cyclase. The  
up-regulation of adenylate cyclase activity occurs through CTA stimulation of ADP ribosylation of the 
adenylate  cyclase  Gsα  subunit  [24].  Increased  intracellular  cAMP  concentrations  result  in  an 
imbalance in electrolyte influx into the cell that is due to decreased sodium uptake by enterocytes and 
an increase in anion efflux from the cells. The decrease in sodium intake, in addition to the extrusion 
of anions and bicarbonates, causes water to be excreted from the cell into the lumen of the intestine. 
Ultimately, large amounts of water and electrolytes are lost from the intestinal epithelium, resulting in 
severe bouts of ―rice water‖ diarrhea. In addition, there is fluid loss from the intestine of up to two Toxins 2010, 2  
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liters per hour, leading to dehydration and death, usually by stroke in patients in which rehydration 
therapy is unavailable.  
2.2. Immunological Activity and Clinical Applications of Cholera Toxin 
Enhanced immunogenic and adjuvant properties of microbial holotoxin B subunits, such as CTB 
and LTB, have been widely reported upon in a number of recent studies  [25–30]. The intact CT 
holotoxin was also found to be a potent mucosal immunogen. The presence of potent CT toxic effects, 
CT resistance to proteases and bile salts, as well as the high affinity of CT binding to ganglioside GM1 
and  corresponding  enzymatic  ADP-ribosylating  activity  may  contribute  individually  or  together 
toward  establishing  the  powerful  immunostimulatory  activity  of  CT  [11].  Despite  its  strong 
immunogenic activity, and its wide use in animal vaccination protocols, the ability of CT to induce 
persistent  inflammation  has  delayed  application  of  the  holotoxin  as  an  adjuvant  for  stimulating 
immune responses in human vaccines.  
Despite  this  present  drawback,  oral  CTB  cholera  vaccines  have  proved  to  be  effective  against 
cholera  toxin  [31].  Surprisingly,  in  addition  to  its  known  capacity  to  induce  a  pro-inflammatory 
response, oral administration of CTB subunit, when coupled with an autoantigen, was shown to induce 
a  state  of  immunological  tolerance  [32,33].  In  early  studies,  oral  delivery  of  CTB  conjugated  to 
specific autoantigens was shown to enhance autoantigen mediated protection of mice against several 
autoimmune diseases, including autoimmune encephalomyelitis [29], autoimmune chondritis [34], and 
uveitis  [35].  Further,  CTB-autoantigen  conjugates  were  shown  to  substantially  suppress  Type  1 
autoimmune diabetes in non-obese diabetic (NOD) mice [36,37]. The results of the diabetes studies 
indicated  that  CTB-autoantigen  conjugates  reduced  IFN-γ  production  and  the  migration  of  Tr1 
regulatory T cells into pancreatic islets [38,39]. Linkage of CTB to an autoantigen was shown to 
provide  up  to  a  10,000  fold  reduction  in  the  amount  of  autoantigen  required  for  generating  
immuno-tolerance [32,40].  
Mechanisms  underlying  CTB-autoantigen  activated  immunological  tolerance  were  shown  to 
include inhibition of dendritic cell (DC) maturation, autoreactive T cell development or stimulation of 
Th2  and  Foxp3  regulatory  T  cell  proliferation  and  activation  [41–43],  or  both.  In  other  studies, 
incubation of immature DCs with CTB was shown to induce DC maturation in experimental tumor 
models  [32,44].  Morphological  changes  in  DCs  incubated  with  CTB  included  cell  enlargement, 
elongation of DC dendrites, and increased migration of DCs into draining lymph nodes, as well as 
increased  expression  of  the  B7-2/CD86  co-stimulatory  molecule  [44].  Further,  the  mucosal 
administration of CTB conjugated to autoantigens was shown to mediate synthesis of T cell cytokines 
in response to the antigen or autoantigen complex. In experimental allergic encephalitis studies, the 
secretion of proinflammatory cytokines IL-12, IFN-γ, and TNF-α were significantly reduced while T 
cell  expression  of  TGF-β  was  increased  in  animals  treated  with  CTB  conjugated  to  myelin  basic 
protein  (MBP)  [29].  Similarly,  immunosuppressive  cytokine  secretion,  including  increased  IL-10 
secretion,  was  observed  after  oral  administration  of  CTB  conjugated  to  insulin,  resulting  in 
suppression of diabetes onset in NOD mice [36,38,45]. Based on the recent findings that inflammatory 
TH17  lymphocytes  were  implicated  in  autoimmune  disease  pathogenesis,  conjugation  of  CTB  to 
myelin oligodendrocyte glycoprotein (MOG), delivered together with Complete Freund’s Adjuvant Toxins 2010, 2  
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(CFA), resulted in suppression of lymphocyte IL-17 secretion [46]. New findings from our laboratory 
show that a fusion gene encoding the cholera toxin B subunit (CTB) linked to the diabetes autoantigen 
glutamic acid decarboxylase (GAD), when delivered by recombinant vaccinia virus inoculation in 
combination with small amounts of IL-10 or complete Freund’s adjuvant (CFA), generates effective 
and  durable  suppression of autoimmune  type 1 diabetes insulitis and hyperglycemia in non-obese 
diabetic  (NOD)  mice  [47].  This  combinatorial  vaccine  approach  is  able  to  completely  suppress 
autoimmune diabetes onset without subjecting the patient to significant levels of systemic IL-10 or 
CFA toxicity. These findings establish a solid basis for clinical assessment of vaccine efficacy in early 
onset  diabetes  patients  and  in  those  prospective  patients  who  are  genetically  predisposed  to 
development of insulin dependent diabetes mellitus (Type 1 diabetes). 
3. Heat Labile Enterotoxin from Enterotoxigenic E. coli (LT)  
3.1. Structure, Pathogenesis and Function 
The Heat labile toxins (LT), produced by enterotoxic strains of E. coli, can be categorized into type I 
(LT-I from now on referred to as LT) and type II (LT-IIa and LT-IIb). Both toxin types are structurally 
and functionally similar to Cholera toxin (CT). As previously stated, LT exhibits extensive amino acid 
homology to CT, while the A subunits of the type II counterparts exhibit amino acid homology to LT-I 
(Figure  2).  Like  CT,  LT  is  an  AB  toxin,  with  one  catalytic  A  subunit  (LTA),  which  binds  to  a 
pentamer  of  non-toxic  B  subunits  (LTB).  Interestingly,  the  first  crystal  structure  of  a  complete 
hexameric AB toxin was that of LT in 1991 [48]. This crystal structure shows that LTA (27 kDa) is 
composed of two subunits joined by a single disulfide bridge: A1, the active catalytic portion, and A2, 
a linker peptide that attaches the A1 subunit to the LTB pentamer (Figure 3). 
Figure 3. The crystal structures of Heat Labile E. coli LT-1(Left) and LT-IIb (Right). The 
A1 subunits are shown in gold and the A2 subunits in yellow. The individual B subunits 
are displayed as red, white, pink, green, and blue ribbon structures. The region containing 
the active-site of each molecule is highlighted by an asterisk and the disulfide bond in the 
A subunit is indicated by black arrows. The structure of Heat Labile E. coli LT is adapted 
from Focco van den Akker et al. 1996 [49]. 
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The secondary structure of LTB plays a role in its function and pentameric subunit association. The 
N-terminus of LTB is an α-helical loop (α1 helix) and has been implicated in various roles in the 
function  of  LTB.  The  N-terminal  α1  helix  is  located  outside  the  core  structure  and  is  linked  by 
disulfide bonds. The N-terminus has been implicated in stabilizing the toxin protein by serving as 
protection against proteolytic degradation [50]. In addition, the GM1 binding site for the holotoxin is 
located near the N-terminus. Deletions in the LTB subunit protein α1 helix, which affect the secondary 
structure, reduce the binding affinity of the B subunit for its GM1 receptor. In addition, the α1 helix 
mutants,  ΔQ3  and  E7G,  greatly  curtail  LTB  secretion  [51].  Most  interestingly,  the  N-terminal 
decapeptide region of each individual subunit has been found necessary for pentamer formation, as 
noted by the inhibition of complex formation observed by antibody blocking of this region [52]. 
The pentameric complex of LTB monomers (11.6 kDa) forms a ring structure with a pore having a 
length of 30 Å and an average diameter of 13 Å [48]. This structure acts as the delivery system for the 
LTA subunit (27 kDa), via interaction with ganglioside membrane receptors on the host cell. Previous 
experiments have shown that LTB has a strong interaction with the ganglioside receptor GM1, which 
is partially facilitated through the free carboxyl of sialic acid on the receptor, as noted by detection of a 
reduction in LTB binding affinity to asialic GM1 [53]. LTB interacts directly with lactose, and exhibits 
high  promiscuity  in  receptor  binding.  In  addition  to  the  GM1  receptor,  LTB  also  interacts  with 
paraglobosides, GM2, polyglycoceramides, and polylactosamine-containing glycoproteins,  although 
with lower affinity [53–57]. Both LT-IIa and LT-IIb are even more deviant in their receptor binding 
specificities. LT-IIa was shown to bind preferentially to ganglioside GD1b, although it may also bind 
GD1a and GM1 with lower avidity [58]. Finally, LT-IIb is known to bind only to receptor GD1d [58].  
The  simultaneous  binding  of  pentameric  LTB  to  five  GM1  ganglioside  receptors  initiates  the 
toxin’s uptake into the cell [54]. The process of toxin endocytosis and translocation to the cytoplasm is 
essential for toxin function. The initiation of toxin endocytosis is connected to the association of GM1 
receptors with lipid rafts embedded in the cell membrane. This localization to lipid rafts is deemed 
necessary for complex uptake [59]. As observed with CT, toxin complex endocytosis may be mediated 
through a variety of uptake pathways including clathrin-dependent, caveolar-dependent pathways, or 
potentially by mechanisms independent of either. The toxin is then trafficked in a retrograde manner, 
eventually reaching the endoplasmic reticulum (ER). From the ER, it is believed that oligosaccharide 
specific sorting allows the LT A1 subunit to be translocated to the cytoplasm, rather than via a protein 
specific pathway [20]. Once in the cytoplasm, disulfide bonds linking LTA1 and LTA2 are reduced, 
liberating the active toxic A1 subunit. Similar to CTA, The catalytic A1 subunit of LT acts as an  
ADP-ribosyltransferase that activates the G protein Gsα. This G protein activation causes cytotoxity via 
the  activation  of  adenylate  cyclase,  which  then  increases  intracellular  levels  of  cAMP  [60].  The 
increased levels of cAMP subsequently causes the well-known pathogenesis of ―rice water‖ diarrhea 
and dehydration characteristic of infected hosts. 
3.2. Immunological Activity and Clinical Applications of LT 
LT interacts with the immune system in various capacities. Fascinatingly, these interactions, which 
are still being characterized, provide LT and more specifically, LTB, particular immunomodulatory 
functions.  This  enterotoxin  and  its  nontoxic  B  subunit  were  shown  to  possess  strong  adjuvant Toxins 2010, 2  
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properties that magnify immune responses towards co-delivered or conjugated antigens. Due to the 
possible LT holotoxin neurotoxicity observed in Bell’s palsy correlation studies, the LTB subunit, 
rather than the holotoxin, should be considered as the dominant focus for future clinical applications 
[61].  Counter-intuitively,  it  seems  that  LT  and  LTB  have  the  potential  for  stimulation  of  either  
pro-inflammatory  or  anti-inflammatory  immune  responses,  depending  on  the  nature  of  the  linked 
antigen.  Thus,  the  relationship  of  LTB  to  future  clinical  applications  may  be  based  on  the 
manifestation of these two capacities. 
The E. coli heat sensitive holotoxin LT, and its toxin B subunit, LTB, may induce immunity by 
different mechanisms. Epidermal-like CaCo-2 cells incubated with LT were shown to inhibit IL-2 
cytokine secretion by T lymphocytes [62]. Further, the antigen presenting capacity of B cells in vitro is 
increased by catalytic LT [63]. The ability of LTB and LT to retain adjuvant capacity is indicative of 
the  toxin’s  interaction  with  other  cell  types.  The  B  subunits  of  LT-IIa  and  LT-IIb  induce  the 
production of IL-8, IL-6, IL-1β, and TNF-α by monocytes [64]. LTB also has the ability to induce high 
levels of TNF-α production by murine macrophages [65]. The other cell type of major interest is the 
dendritic  cell,  which  is  thought  to  be  an  arena  for  toxin  subunit  adjuvant  activity.  Incubation  of 
immature DCs with LT-IIb-B induces TLR-2 dependent activation, as marked by DC costimulatory 
factor CD86, CD80, and CD40 upregulation [66]. These activated DCs have the capacity to increase 
CD4+ T cell proliferation [67]. Adjuvant potency is further realized by LT’s ability to mediate DC 
migration. Experiments have shown that LT induces a localization of DCs to the follicle-associated 
epithelium of the Peyer’s patches [68]. This result may help to explain the observed increase of antigen 
uptake into DCs associated with adjuvant/antigen co-delivery.  
The practical applications of mucosal subunit vaccines are becoming increasingly apparent. The use 
of LTB as an adjuvant molecule in the development of vaccines against a variety of diseases has 
recently  been  assessed.  In  conjunction  with  viral  vaccines,  LTB  was  used  to  increase  immune 
responses and serum antibody titers. Administration of the influenza vaccine A/H5N1 with an adjuvant 
LT patch at the delivery site was shown to be safe. The treatment conferred greater serum antibody 
titers in patients [69]. This observation opens up the possibility of using LTB enterotoxin B subunit 
adjuvants to enhance inflammatory immune responses for other viruses, such as HIV [70]. In addition 
to  preventive  therapy  for  viral  infection,  LTB  conjugates  have  demonstrated  the  ability  to  confer 
protection against bacterial infections. LTB fused with several T and B cell epitopes from H. pylori, 
and delivered orally as a vaccine into mice, decreased bacterial colonization upon H. pylori challenge 
[71]. Further advancement in the field of subunit vaccination can be seen in the use of LTB as an 
adjuvant  in  the  prevention  and  treatment  of  cancer  and  neurodegenerative  diseases.  For  example,  
LTB-CEA  (carcino-embryonic  antigen)  fusion  protein  exhibit  antitumor  protective  effects  when 
administered before a tumor challenge [72]. Even more promising are the current clinical trials, in 
which  a  mutant  LT  (R192G)  adjuvant  is  co-delivered  with  peptides  from  amyloid-beta  for  the 
treatment of Alzheimer’s disease [73].  
Another major area of LTB and some LT mutant adjuvant development involves immune tolerance 
and  modulation  of  the  immune  system  towards  an  anti-inflammatory  state.  This  type  of  adjuvant 
activity  is  directly  applicable  to  autoimmune  disease.  Specifically,  LTR72,  a  partially  detoxified 
mutant, was shown to inhibit development of TH1 cells and to augment the activation of TH2 cells  
in vitro [74]. In mouse models, LTB provided protection from both autoimmune uveoretinitis and Toxins 2010, 2  
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encephalitis via co-administration with and direct linkage to the auto-antigen, respectively [75,76]. Our 
laboratory  has  shown  that  administration  of  LTB  adjuvant  protein  fused  to  glutamic  acid 
decarboxylase (GAD), as well as CTB-GAD and STB-GAD, is able to mediate suppression of Type 1 
diabetes  development  in  NOD  mice  [77].  A  current  interest  is  in  establishing  a  method  for  oral 
administration of subunit vaccines in geographic areas with less or no present access to healthcare. 
Edible plants transformed with genes encoding the desired adjuvant and antigen fusion protein present 
an ideal route. The expression of various vaccine combinations linked genetically to LTB as an adjuvant 
have been synthesized in edible plants, including potatoes, carrots, lettuce, rice, and corn [78–82]. These 
plant production and delivery vehicles could provide an optimum route for exploiting the adjuvant 
potential of bacterial enterotoxins. 
4. Shiga and Shiga-like Toxins  
4.1. Structure Pathogenesis and Function 
For  many  years,  Shiga  toxin  (named  after  Kiyoshi  Shiga,  a  Japanese  bacteriologist,  who  first 
identified Shigella dysenteriae as the cause of inflammatory dysentery diarrhea), was thought to be 
exclusively produced by  Shigella bacteria [83]. However, it is now known as a toxin family that 
includes Shiga toxin and other closely related toxins. Shiga toxin (Stx) is produced by S. dysenteriae, 
while  Shiga-like  toxin-1  (Stx1)  and  Shiga-like  toxin-2  (Stx2)  are  produced  by  Enterohemorrhagic 
Escherichia coli (EHEC) or Shiga toxin producing E. coli (ETEC) [84–86]. The infamous E. coli strain 
O157:H7 that causes severe human diarrhea or dysentery belongs to the type of E. coli that produces 
Stx2 [85]. Common characteristics shared among these bacterial strains are that they are Gram-negative, 
rod-shaped, anaerobic, and non-sporulating [84].  
Shiga  toxin  is  a  hexameric  protein  with  a  molecular  mass  of  70.5  kDa.  It  is  composed  of  an 
enzymatic subunit StxA monomer and a receptor-binding StxB homopentamer (Figure 4). While StxA 
is 32 kDa, each StxB subunit of the pentamer is 7.7 kDa [87]. Within the StxA subunit, there are two 
fragments covalently associated by a single disulfide bridge: A1 (28 kDa) and A2 (4 kDa) [85,88]. 
How those subunits associate to form the holotoxin is shown in Figure 4. The C-terminus of the A2 
fragment is responsible for AB subunit association: the Leu282, Gly283, Ala284, Ile285, Leu286, and 
Met287 residues that partially penetrate the StxB subunit [89] are especially involved. The toxic A1 
fragment has significant amino acid sequence homology to the A subunit of the plant enterotoxin, 
ricin,  and  is  similar  to  it  at  both  structural  and  functional  levels  (Figure  2)  [89,90].  The  Stx  A1 
fragment and ricin toxin both depurinate adenosine in the 28S ribosomal RNA of the 60S ribosomal 
subunit. This modification makes tRNAs that are unable to associate with the ribosomal complex, 
which  ultimately  leads  to  the  inhibition  of  protein  synthesis  in  target  cells  [85,86,89,90].  When 
dissociation of tRNA from the ribosome occurs, JUN N-terminal kinase (JNK) and mitogen activated 
protein kinase (MAPK) p38 are activated, leading to an alternation of extracellular signal-regulated 
kinase  (ERK)-1  and  ERK-2  signaling  pathways  [85].  When  epithelial  cells  are  targeted,  the  
p38-dependent pathway induces IL-8 secretion, and when the target cell is a monocyte, GM-CSF and 
TNF-α secretion are induced in a p38 pathway dependent manner [85]. However, in order to fully Toxins 2010, 2  
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obtain enzymatic activity of the A1 fragment, the StxA subunit must be proteolytically cleaved in the 
Golgi cisternae at the A1-A2 disulfide bridge [89].  
Figure 4. The crystal structure of Shiga toxin (Stx) protein. The A subunit StxA (blue), is 
composed of two peptide fragments covalently associated by a single disulfide bond: A1 
(28 kDa) and A2 (4 kDa) [26,31]. Cleavage in the Golgi apparatus of these two fragments 
at Cys242–Cys261 is required for the activation of the A1 fragment [20,26]. The individual 
StxB  subunits  associate  to  form  a  homopentamer,  with  each  individual  StxB  subunit 
possessing a molecular weight of 7.7 kDa [27]. 
 
The StxB  subunit is  a symmetric homopentameric ring composed  of five identical B subunits. 
However, despite its symmetric structure, StxB associates with StxA asymmetrically by having only 
three of its B subunits interacting with the C-terminus of the A2 fragment, thus making StxA bend to 
the side opposite from the three B subunits (Figure 4) [89]. This conformation is seen in the B subunits 
of other AB toxins, which bind to specific receptors with specific glycolipids or glycoproteins. StxB 
preferentially binds to globotrioylceramide (Gb3) and facilitates the internalization of StxA into the 
target cell [85,89]. However, it has been found recently that StxB, which was believed to be the  
non-toxic subunit of Stx, actually has significant toxic activity in the target cell. The toxicity of the 
StxB subunit consists of DNA cleavage that leads to apoptotic cell death [90]. Apoptotic cell death 
appears to occur via a caspase 8/3 or 8/3/6 cascade pathway, in addition to decreased expression of 
survival  factor  B-cell  lymphoma-2  (Bcl-2)  and  an  increase  of  the  TNF-related  apoptosis-inducing 
ligand (TRAIL), followed by Ca
2+ release from the ER [85]. 
The cell entry mechanism for Shiga toxin proteins is via a retrograde transport system, which was 
first elucidated by a study focused on Stx entry into cells [90,91]. Stx binds to Gb3 ganglioside in lipid 
rafts on the target cell membrane and initiates endocytosis. Stx is then carried into the trans-Golgi 
network (TGN) through the perinuclear endocytic recycling compartment (ERC) by clathrin-coated 
vesicles. From the TGN, Stx travels to the ER in coat protein complex I (COPI)-coated vesicles. 
However, unlike other AB toxins, such as cholera toxin, that depend on KDEL (a lys-asp-glu-leu amino 
acid sequence) to facilitate retrograde transport to the ER, Stx appears to remain KDEL-independent Toxins 2010, 2  
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[86,90]. Once Stx enters the ER lumen, it links with a pre-associated large multi-chaperone complex of 
HEDJ, BiP, and a 94 kDa glucose-regulated protein (GRP94), in order to partially unfold so that the 
ER  can  recognize  it  as  a  misfolded  protein  and  excrete  it  into  the  cytosol  via  ERAD.  Typically, 
misfolded proteins are degraded by the proteosome. However, Stx lacks lysine residues and cannot be 
ubiquitinated. Therefore, proteosomes do not see the toxin as a target and Stx maintains its enzymatic 
activity in cytosol of the target cells [85,86,90]. The proteolytic cleavage of StxA at Cys242–Cys261 
for the activation of the toxic A1 fragment is accomplished in vesicles of the Golgi apparatus by a 
proteolytic enzyme furin, along with glycosylation in the ER during retrograde transport from the 
Golgi to the ER [85,90]. 
4.2. Immunological Activity and Clinical Applications of Shiga Toxin 
From extensive studies of Stx functions, it is known that the toxin interacts with antigen presenting 
cells (APC), predominantly dendritic cells and macrophages, and induces APC expression of costimulatory 
factors CD40, 80, 83, and 86 and major histocompatibility complex (MHC) classes I and II [90]. In 
addition,  Stx  is  known  to  induce  inflammatory  cytokine  IL-1,  IL-6,  and  TNF-α  secretion  by 
macrophages [86]. At present, the type of immune response that Stx induces downstream of those 
antigen presenting cells remains inconclusive. Haicheur et al. demonstrated that when splenocytes 
stimulated with StxB-OVA recombinant protein were co-incubated with OVA specific CD4
+ T cells, 
both IL-2 and IFN-γ secretions were enhanced, indicating that a Th1-type response was induced by the 
StxB subunit [92]. Additionally, Ohmura et al. showed that bone marrow derived DCs (BMDCs) 
incubated with either Stx1 or its B subunit (StxB1) differentially induce Th1-, Th2-, and possibly 
Th17-type responses, as demonstrated by the types of cytokines secreted [87,93]. Further, the same 
authors found that BMDCs incubated with StxB1 induced secretion of TNF-α and IL-12p70. When 
BMDCs stimulated with Stx1 were co-incubated with CD4
+ T cells, secretion of IL-4, IL-5, IL-6, IL-10, 
and INF-γ cytokines was induced. However, when BMDCs stimulated with StxB1 were co-incubated 
with CD4
+ T cells, only IL-6 secretion was significantly enhanced [93]. These results confirm that 
Stx1 is capable of inducing both Th1 and Th2-type responses [93]. Also, StxB1 appears to skew the T 
cell  population  towards  an  inflammatory  Th17  phenotype,  as  IL-6  is  one  of  the  early  cytokines 
secreted  by  Stx  inoculated  DCs,  and  is  essential  for  Th17  cell  differentiation  [87].  In  addition, 
cytokines induced by Stx, especially IL-1 and TNF-α, can induce synthesis of Gb3, which attracts the 
binding of additional Stx molecules. Thus, a positive feedback loop for increasing target cell sensitivity 
may be a possibility [86]. 
Based on the internalization mechanism of StxA subunits, recombinant protein vaccines have been 
designed that deliver antigen epitopes into the ER lumen for presentation to T cells by MHC class I 
receptors that present them on the cell surface [86,90]. Antigen presentation induces in turn the CD8
+ 
cytotoxic T cell responses [85,94]. Further, as demonstrated by Adotevi et al., co-administration of 
StxB-antigen recombinant protein with α-galactosylceramide (α-GalCer) increases the efficiency of 
antigen  delivery  during  StxB-mediated  internalization.  This  approach  required  only  50  ng  of 
immunogen  dosage  to  induce  a  CD8
+  cytotoxic  T  cell  response  [94].  Most  importantly,  when 
transgenic mice that produce OVA were co-stimulated with StxB-OVA and α-GalCer, CD8
+ T cells 
specifically active against OVA were detected. This result suggests that StxB recombinant protein Toxins 2010, 2  
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delivered with α-GalCer may induce immune responses to microbial diseases, and also against tumors 
that require recognition of self-antigens, through modulation of the immune system by immunogenic 
proteins fused to the StxB subunit [85,94]. 
In another example of StxB recombinant vaccines, Oloomi et al. showed that by immunizing mice 
with  a  fusion  protein  encoding  aggregative  adherence  fimbria  (StxB-AAF),  a  humoral  immune 
response was mounted against bacteria that use AAF to colonize epithelial cells. In addition, immunity 
against a lethal dose of Shiga toxin was also generated [95]. Because there are no vaccines against 
Shiga toxin producing bacteria established to date, this technique could be useful for arresting disease 
onset  by  inhibiting  the  colonization  and  progression  of  bacterial  invasion  through  induction  of  a 
humoral immune response specifically against Shiga toxin [95]. 
The StxA subunit can also be used as an adjuvant in recombinant StxA subunit vaccines, which 
may target specific cells, depending on what kind of protein is fused to StxA [85,90]. One example of 
this type of subunit vaccine is the recombinant protein StxA-CD4. The acquired immune deficiency 
syndrome (AIDS) causing virus HIV-1 uses its coat glycoprotein, gp120, to bind CD4 on the surface 
of leukocytes, including T helper cells and dendritic cells. These infected immune cells present gp120 
on their cell surface. By fusing StxA with CD4 cell derivative peptides, StxA toxicity may be delivered 
specifically to infected cells without incurring damage to healthy uninfected cells [70,96]. In all, the 
use of STX and its subunits as adjuvants for the induction of immunity is becoming more defined. 
5. Pertussis Toxin  
5.1. Structure, Pathogenesis and Function 
Pertussis  Toxin  (PT),  a  protein  synthesized  by  the  Gram-negative  coccobacillus  Bordetella 
pertussis, is primarily toxic to epithelial cells of the respiratory tract [97,98]. B. pertussis is a strict 
human  pathogen  known  to  be  responsible  for  Whooping  Cough,  a  highly  contagious  childhood 
respiratory disease named after the unusual low-pitched, distinctive repetitive cough  expressed by 
infected  patients.  The  bacterial  pathogen  responsible  for  Whooping  Cough  was  first  identified  as 
Bordetella  pertussis  by  the  Belgian  scientist,  Jules  Bordet,  in  1906  [99].  Because  early  pertussis 
vaccines were constructed from attenuated bacteria, there was a concern that immunized adults may 
double as carriers of the pathogen and be responsible for the infection of new born infants not yet 
immunized [84]. However, in the United States, an acellular diphtheria, tetanus, and acellular pertussis 
―toxoid‖  vaccine  (DTaP)  was  adopted  by  the  Center  for  Disease  Control  (CDC)  to  reduce  the 
opportunity for infection of infants [100].  
Pertussis toxin has a six membered oligomeric structure (Figure 5). The single pertussis A subunit 
displays enzymatic activity that transfers ADP-ribose from nicotinamide adenine dinucleotide (NAD) 
to  the  cysteine  residue  of  trimeric  guanine  nucleotide-binding  proteins  (G-proteins),  leading  to  a 
decoupling of the G-protein α-subunit from its receptor. Subsequently, this decoupling event prevents 
the  inhibition  of  adenylate  cyclase  activity,  resulting  in  an  increase  of  intracellular  cAMP 
concentration [97,101,102]. Other AB toxin A subunits, for example the A subunit of the heat-labile 
enterotoxin (LT) from Escherichia coli, share a similar function, with the exception that the LTA 
subunit protein attacks an arginine residue in G-proteins rather than a cysteine residue [97]. In contrast Toxins 2010, 2  
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to the toxic enzymatic function of the A subunit, the pertussis B subunit (PTB) binds preferentially to 
receptor glycoproteins and glycolipids, such as ganglioside GD1a, which is located within lipid rafts 
embedded in the host cell plasma membrane [97,103]. The binding of PTB to its receptor is believed to 
initiate retrograde transport of the pertussis A subunit (PTA) or PTB through the trans-Golgi Network 
(TGN) to the endoplasmic reticulum (ER), or both [23,98,101,104]. As PTA travels through the TGN, 
it undergoes tyrosine sulfation and N-glycosylation in the Golgi apparatus and ER, respectively, in 
order to fully establish ADP-ribosylating ability [97]. In addition, in a manner similar to other toxins 
like cholera toxin (CT) and Shiga toxin (Stx), PTA is believed to be partially unfolded in the ER lumen 
so that the ER recognizes it as a misfolded protein and excretes it into the cytosol for endoplasmic 
reticulum associated protein degradation (ERAD) [23,101]. Just like StxA, PTA lacks lysine residues 
and cannot be ubiquinated. Therefore, ERAD cannot recognize PTA as a target. Thus, PTA evades 
degradation in the proteosome and can initiate its toxic enzymatic function [23,102]. 
Figure 5. The crystal structure of pertussis toxin (PT). The PT protein subunits associate in 
a  hexameric  configuration  with  a  combined  molecular  weight  of  105  kDa.  The  PT 
subunits; S1 (blue), S2 (green), S3 (pink), S4 (yellow and purple), and S5 (turquoise); 
associate in the ratio 1:1:1:2:1. The S1 subunit is pyramidal and is composed of the A 
subunit (PTA) with a molecular weight of 28 kDa [9,30]. The PTB subunit is composed of 
S2  (23  kDa),  S3  (22  kDa),  two  S4’s  (11.7  kDa  each),  and  an  S5  (9.3  kDa)  oligomer 
[30,32], creating an asymmetrical heteropentameric ring structure [2,6,9,11].  
 
The majority of the pertussis toxin AB subunit associating region is the flat basal portion of a 
pyramidal PTA subunit sitting on an asymmetric heteropentameric ring of the PTB subunits. At the 
center of this PTB ring, five helices create a hole where short extended strands of PTA (β10, 11, and 12) 
partially penetrate [97]. Unlike the majority of AB toxins, PT does not require proteolysis for activation 
of its A subunit. However, reduction of the disulfide bond between Cys41 and Cys201 is essential for 
enzymatic function. This observation is consistent with the idea that a region near Cys201 must shift in 
order for NAD and G-protein to have access to the active site of PTA. Within the active site, Glu129, 
Cys 41, and Trp26 are believed to interact with NAD and Arg9. In addition, Asp11, Arg13, and Phe23 
are also important for maintenance of conformation of the toxin’s active site [97]. 
Within PTB, five subunits (S2, S3, two S4s, and S5) are associated into three distinctive groups: 
S2/S4 dimer, S3/S4 dimer, and S5 monomer. Both S2 and S3 are known to be 70% identical in amino Toxins 2010, 2  
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acid sequence, and the Cys27–Cys83 region has significant homology to rat mannose binding protein 
(MBP),  which  belongs  to  the  C-type  lectin  family.  This  homologous  region,  based  on  lectin’s 
carbohydrate recognition domain (CaRD), is believed to provide PTB’s sugar specific binding for 
adherence to the host cell membrane [97]. Furthermore, the properties of S2 and S3 subunit penetration 
of host cell lipid rafts may be involved in facilitation of PTA (S1 subunit) internalization [105]. 
5.2. Immunological Activity and Clinical Applications of Pertussis Toxin 
Interestingly,  although  PTA  and  LTA  share  extensive  amino  acid  sequence  homology,  the 
conformation  of  their  B  subunits  is  completely  different.  As  seen  in  Figure  2,  PTA  and  LTA 
associations to B subunits are rotated 180° , which results in a detectable difference in the active site 
conformation that, in turn, results in a difference in the target residues: cysteine (PT) and arginine (LT) 
[97].  This  difference  in  structure  provides  the  basis  for  PT  and  PTB’s  alternate  interaction  with  the  
immune system. 
Both PT and PTB differentially activate dendritic cells (DCs) by stimulating the Toll-like membrane 
receptor (TLR)-4 [106]. The pertussis toxin B subunit preferentially triggers activation of the adaptor 
protein  myeloid  differentiation  primary  response  gene  (MyD88)-independent  pathway,  leading  to 
induction of chemokine ligand (CXCL or IP)-10. Thus, PT can trigger both MyD88-independent and 
MyD88-dependent pathways. Subsequently, PT induces not only IP-10, but also pro-inflammatory 
cytokines  IL-6,  TNF-α,  and  IL-12  [106].  Fujimoto  et  al.  and  Hou  et  al.  demonstrated  that  DCs 
stimulated with PT upregulate cytokines IL-12, IL-6, IL-1β, IFN-γ, and TNF-α, resulting in only small 
amounts of IL-10 and almost no IL-4 secretion. Under these conditions Th1 inflammatory immune 
responses are favored [107,108]. 
As previously demonstrated by Chen et al., PT stimulation of CD4
+CD25
+ T cells suppressed both 
Foxp3
+ expression and IL-2 secretion. Further, it was found that PT also decreased the number and 
function  of  lymphocytes  that  suppress  CD4
+CD25
-  T  cells.  Because  IL-2  is  one  of  the  critical 
cytokines that support T regulatory (Treg) cell differentiation and proliferation, the immune system 
could,  in  general,  be  skewed  towards  a  more  inflammatory  condition  due  to  decreased  Treg  cell 
availability [109].  
Based on the ability of PT to stimulate a Th1 lymphocyte favored environment upon interaction 
with dendritic cells and T cells, PT has been extensively studied for its immunological adjuvanticity. 
However, due to the strong toxicity of the PTA subunit, the non-toxic PTB subunit is favored for use 
as  an  adjuvant  [109]. Immunization experiments  with  PT-adjuvant  fusion proteins  were  shown  to 
suppress  Th1-mediated  organ  specific  autoimmune  diseases,  including  experimental  autoimmune 
encephalomyelitis (EAE) and experimental autoimmune uveitis [70,109]. As observed with complete 
Freund’s  adjuvant  (CFA),  PT  can  increase  the  permeability  of  the  blood-brain  barrier  (BBB)  to 
leukocytes. With its ability to modify  BBB permeability, PT was shown to enhance a CD4
+ Th1  
cell-mediated inflammatory response in the central nervous system (CNS) when EAE-susceptible mice 
were co-immunized with myelin basic protein, CFA, and PT [109]. 
In addition to its adjuvanticity, PT has shown potential for fighting human immunodeficiency virus 
type 1 (HIV-1) infection. Pertussis toxin was found to inhibit HIV-1 infection in two ways: both  
pre- and post-entry of the virus into host cells [70,110]. In the pre-entry stage, PT, especially PTB, can Toxins 2010, 2  
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inhibit R5 HIV-1 entry to primary CD4
+ T cells via densitization of CC chemokine receptor type 
(CCR)-5,  leading  to  uncoupling  of  CCR-5  from  CD4,  a  primary  receptor  for  HIV  [70,110]. 
Secondarily, PTB can also inhibit HIV-1 infection through down-modulation of HIV replication. Both 
Tat-dependent HIV transcription and the stability of subsequent HIV mRNA products are inhibited by 
PTB [70,111]. PTB is related to post-entry HIV-infection inhibition and can thus also interfere with 
latent  HIV-1  multiplication  in  chronically  infected  cells  through  the  Activator  Protein  1  (AP-1) 
dependent pathway [112]. These observations reveal the increasing need for research involving the use 
of PTB as an adjuvant. 
6. Anthrax Toxin 
6.1. Structure, Pathogenesis and Function 
Anthrax is an AB enterotoxin produced by the Gram positive bacteria, Bacillus anthracis. Unlike 
other AB toxins described thus far in this review, anthrax toxin has a tripartite structure, consisting of 
three independent polypeptide chains. These three subunits are denoted as edema factor (EF), lethal 
factor (LF)—both of which have enzymatic activity—and protective antigen (PA). The cytotoxic and 
immunogenic  functions  of  anthrax  are  coupled  to  these  subunits’  molecular  structures  and  
their interactions. 
Although PA lacks enzymatic activity, it functions to facilitate entry of the LF and EF subunits into 
the host cell. The PA subunit is initially produced as an 83 kDa polypeptide (PA83) that binds to either 
of two identified anthrax receptors, tumor endothelial marker 8 (TEM8 or ANTXR1) or capillary 
morphogenesis 2 (CMG2 or ANTXR2), [113]. Upon binding to its receptor, PA is processed by the 
host endoprotease furin into a 63 kDa form (PA63) [114]. This processed form of PA is biologically 
active,  and  in  conjunction  with  its  receptor,  self-associates  into  a  heptameric  pre-pore  structure 
(PA63
7mer) (Figure 6a). The water soluble heptamer is 85 Å high with a pre-pore average diameter of 
160 Å, and a lumen average diameter of 35 Å [115]. The oligomerization of PA also induces the seven 
bound receptors to cluster in lipid rafts or detergent-resistant membrane microdomains implicated in 
toxin complex endocytosis [116]. The PA heptameric complex competitively binds up to three LF 
and/or EF subunits (Figure 6d) [117]. The binding of LF or EF to the pre-pore structure triggers 
activation of src-like kinases to initiate its uptake and induction of a conformational change in the PA 
heptamer that may later facilitate LF and EF translocation into the cytoplasm [118,119]. Once the 
receptor is activated, the anthrax complex is endocytosed via ubiquitin, actin, and clathrin dependent 
mechanisms and is then fused with an endosome [120]. Following toxin uptake, formation of a pore in 
the endosome bilayer is required for LF and EF transport into the cytoplasm. Translocation of LF and 
EF into the cytoplasm has been shown to be pH specific. This pH sensitivity is due to the protonation 
of His-121 and Glu-122 amino acid residues that permit disruption of a specific salt bridge. Disruption 
of the salt bridge results in decreased stability of PA and receptor interactions, leading to detachment 
of PA domain II, a peptide segment necessary for pore formation [121].This pore, which develops via 
protonation  of  negative  amino  acid  residues,  acts  as  a  proton/protein  symporter  that  drives 
translocation of LF and EF into the cell cytoplasm [122]. Before translocation, both LF and EF must 
be unfolded in order to fit through the lumen of the PA63
7mer pore, as shown by the presentation of Toxins 2010, 2  
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barriers to unfolding, causing blockage of translocation [123]. Experiments have shown that the rate 
limiting  step  of  LF  translocation  is  in  the  unfolding  of  the  amino-terminal  beta-sheet  subdomain 
catalyzed by the Phe-clamp active site of the PA63
7mer pore [124,125]. Translation of both LF and EF 
into the cytoplasm is initiated at the N-terminus [126]. Once in the cytoplasm, LF and EF exert their 
cytotoxic effects.  
Figure 6. Computer modeled top-down view of anthrax toxin protective antigen (PA63),  
63  kDa  heptamer  is  presented  in  panel  (A).  The  PA  monomer  is  comprised  of  four 
domains. A hydrophobic region implicated in LF and EF binding is exposed after furin 
cleavage  in  Domain  I  (blue),  the  N-terminus.  Domain  II  (pink)  is  the  heptamerization 
domain that contains a flexible loop thought to contribute to  membrane insertion. The 
function of Domain III (yellow) is currently unknown, while Domain IV (purple) is the  
C-terminus,  which  comprises  the  receptor  binding  site  (Image  credit:  R.  John  Collier, 
Harvard  Medical  School).  Panel  (B)  is  the  Anthrax  edema  factor  protein  bound  to 
calmodulin. The catalytic edema factor is represented in light blue while calmodulin is 
depicted in turquoise. Panel (C) is the Anthrax lethal factor (LF). Domains I-IV of LF are 
indicated as 1-4, respectively. A representative sequence of MAPKK-2 is located within 
the active site next to domain IV. Panel (D) contains a computational prediction of anthrax 
holotoxin structure. Both a side view (left) and top-down view are shown (right) (Image 
credit: T. Nguyen, National Cancer Institute [127]). 
 
Lethal Factor (LF) is a zinc-dependent metalloprotease that targets mitogen-activated protein kinase 
kinases  (MAPKKs)  [128,129].  The  LF  polypeptide  contains  four  domains,  the  fourth  of  which 
contains  the  active  site  (Figure  6c)  [130].  LF  exhibits  its  toxic  activity  by  specifically  cleaving 
MAPKKs within the N-terminal proline-rich region that precedes the kinase domain. Protein cleavage 
specificity  is  achieved  by  recognition  of  a  peptide  consensus  motif  marked  by  a  sequence  of 
hydrophobic residues followed by basic residues [131]. Via cleavage, LF is able to disrupt MAPKK 
phosphorylation activity. Because MAPKKs are important in major signal transduction pathways, this 
disruption leads to a decrease in transcription and subsequent protein synthesis.  Toxins 2010, 2  
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Edema  factor,  the  other  catalytic  subunit  of  anthrax  toxin,  acts  as  a  calcium  independent 
calmodulin-dependent adenylate cyclase that functions by increasing the intracellular concentration of 
cAMP [132,133]. Recent analysis of the crystal structure of EF bound to calmodulin (EF-CaM) reveals 
much about the activity of the enzyme (Figure 6b). Although structurally different from mammalian 
adenylate cyclases, EF-CaM uses a two-metal-ion catalysis reaction that is partially facilitated through 
a histidine, which initiates the deprotonation of ATP [132]. Together, with the metalloprotease activity of 
LF, the increased levels of cAMP resulting from EF-CaM activity produce a variety of cytotoxic effects 
that include altered water homeostasis, which significantly disturbs intracellular signaling pathways. 
6.2. Immunological Activity and Clinical Applications of Anthrax 
For B. anthracis to attack the host, anthrax toxin dismantles the first line of host defense, the innate 
immune system. Phagocyte chemotaxis is potently inhibited by the pertubation of chemokine receptor 
signaling [134]. Alternatively, EF greatly impairs neutrophil actin-based motility and also inhibits 
endothelial cell chemotaxis via indirect activation of Epac and Rap1 [135,136]. Previously shown by 
Kim and  Bockoch, it is possible  that anthrax EF inhibits Nox1 mediated  reactive oxygen species 
(ROS) formation in gut epithelial cells, therefore circumventing an innate immune response in host 
epithelial cells [137]. Anthrax also has a similar effect on phagocytes. ROS and cytokine production 
necessary for macrophage function is inhibited by EF and LF, respectively, due to their dependence on 
the MAPK pathway [138]. Additionally, LF induces caspase dependent apoptosis of macrophages, 
which is aided by the circumvention of survival signaling cascades [139,140]. It is interesting to note 
that  alveolar  macrophages  display  a  resistance  to  anthrax  toxin  action,  most  likely  due  to  low 
ANTRX1 and ANTRX2 expression [141]. 
Dendritic  cells  (DCs)  are  antigen  presenting  cells  that  can  be  considered  to  be  both  an  initial 
receptor for identifying pathogen attack and a bridge between innate and scalable adaptive immunity. 
Lethal factor impairs DC MHC antigen presentation via the ERK1/2 MAPK pathway [142]. In addition, 
LF causes a distinct downregulation of costimulatory factors CD80, CD86, and CD40, as well as down 
regulation  of  several  inflammatory  cytokines  [143,144].  In  the  presence  of  EF,  which  is  known  to 
upregulate DC costimulatory factors, LF is still able to suppress DC activation. Dendritic cell maturation, 
as  marked  by  CD83  synthesis,  is  induced  by  EF  either  alone  or  in  combination  with  LF  [145]. 
Suppression of the adaptive immune response is further exacerbated by the ability of EF to upregulate 
ANTRX1  mRNA  expression  and  subsequently,  protein  availability  [146].  The  high  expression  of 
ANTRX1 receptor permits larger amounts of anthrax toxin to be taken up by DCs. A consequence of this 
mechanism is the initiation of caspase-3 dependent apoptosis of human DCs by LF [147]. 
The suppression of adaptive immunity by anthrax toxin is an essential part of B. anthracis evasion 
of  the  host  immune  response.  Both  LF  and  EF  act  directly  on  T  lymphocytes  by  altering  their 
immunogenic  functions.  In  the  presence  of  these  anthrax  toxin  subunits,  both  proliferation  and 
cytokine production of activated T cells are greatly inhibited [148]. Also, anthrax toxin disrupts T cell 
receptor initiated activation via the MAPK pathway. Further, MAPK dependent IL-2 production is also 
inhibited [149,150]. Due to their dependence on helper T cells, activation of B lymphocytes is blocked 
by anthrax toxin. In addition, anthrax toxin can directly affect B cell function by targeting the MAPK 
pathway. Thus, LF is able to potently inhibit B cell proliferation and antibody production [151]. Toxins 2010, 2  
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The mechanism of host immune suppression employed by anthrax toxin opens the possibility of 
using its subunit, PA, as a safe and effective adjuvant. Similar to other AB toxins and their subunits, 
there  is  promise  that  PA  may  have  the  ability  to  act  as  both  an  anti-inflammatory  or  as  a  
pro-inflammatory immunomodulator, depending on the antigen or autoantigen to which it  may be 
conjugated.  The  recent  demonstration,  with  an  oral  administration  of  PA  conjugated  to  the  
poly-γ-glutamic  acid  (GPA)  capsule  peptide,  shows  that  PA  can  be  used  as  a  vaccine  to  induce 
protection against lethal doses of anthrax toxin in guinea pigs, which lends further support to these 
notions [152]. Due to the controversy surrounding the toxin subunit’s ability to elicit contradictory 
responses, this field remains available for exploration. To realize the full potential of PA and other AB 
toxin subunits to serve as adjuvants for treatment of  infectious and autoimmune  diseases, a more 
complete investigation will be required.  
7. Ricin Toxin 
7.1. Structure, Pathogenesis and Function 
Ricin enterotoxin is the prototypical lectin toxin. It is synthesized abundantly in the castor oil plant 
(Ricinus communis). Additional plant species, including Abrus precatorious (Rosary pea), synthesize a 
lectin enterotoxin molecule (Abrin) almost identical in protein structure and action to ricin. Ricin 
enterotoxin  exists  in  several  isoforms,  including  ricin  D,  ricin  E,  and  the  closely  related  ricinus 
communis  agglutinin  (RCA)  molecules  [153,154].  Similar  to  Shiga  toxin  in  its  mode  of  action 
(Figure 7), ricin holotoxin contains a catalytically active ribosome-inactivating 32 kDa A chain (RTA) 
linked by several disulfide bonds to a galactose-binding lectin B subunit 34 kDa (RTB). In contrast to 
other bacterial AB toxins, the RTA holotoxin is a tetrameric toxin consisting of two separate ricin-like 
heterodimers containing only RCA subunits [155]. Thus, RCA is a strong hemaglutinin, but a rather 
weak toxin [155].  
Figure 7. The crystal structure of ricin enterotoxin protein showing the A subunit (blue) 
and  B  subunit  (gold)  polypeptide  chains.  Ricin  contains  a  catalytically  active  
ribosome-inactivating  32  kDa  A  chain  (RTA)  linked  by  disulfide  bonds  to  a  
galactose-binding lectin B subunit 34 kDa (RTB) [156]. 
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Ricin toxin is synthesized as a single polypeptide that is cleaved into both A and B subunits. The 
ricin toxic A subunit was discovered to be an N-glycosidase that depurinates specific adenine residues 
in rat 28S rRNA and in the 23S rRNA from E. coli [157]. Recent experimental evidence suggests ricin 
depurinates the eukaryotic ribosome by employing different docking sites on the ribosomal stalk. In 
Saccharomyces cerevisiae, surface Plasmon Resonance was used to show that the RTA subunit of ricin 
binds to the P1 and P2 proteins for its cytotoxicity [158]. The toxin does not, by itself, degrade RNA 
chains. However, depurination makes the RNA susceptible to hydrolysis at both an alkaline pH, and in 
an acidic environment [159]. As a result, the subunit is able to inactivate several thousand ribosomes 
faster than the cell can construct new ones [160]. In ricin as well as other type 1 ribosome inactivating 
proteins (RIP), a number of highly conserved residues, such as Glu177 and Arg 180, are important for 
enzymatic activity of the A subunit [161,162]. 
The galactose specific-lectin RTB subunit is responsible for binding ricin to both glycoprotein and 
glycolipids on the cell surface. The promiscuous binding of ricin to a wide variety of galactosidases 
and glycoproteins makes it difficult to identify specific ricin receptors. Also, it is known that ricin 
receptors are highly proteinaceous [163]. The lectin nature of ricin enhances cellular attachment and 
endocytosis of the toxin [164,165]. Experimental evidence has shown that several mechanisms of ricin 
endocytosis are cholesterol dependent [166]. The removal of cholesterol from the plasma membrane or 
the addition of cholesterol-binding drugs, such as filipin, results in the disappearance of caveolae and 
the inhibition of material uptake of clathrin pits [167]. 
One  well  characterized  pathway  leading  from  endosomes  to  the  Golgi  apparatus  is  the  
Rab9-dependent pathway from late endosomes to the Golgi apparatus [168]. Ricin transport was found 
to be independent of rab9, but sensitive to MβCD [169,170]. Ricin transport was also shown to occur 
via rab5 dependent vesicles [171]. Taken together, the experimental evidence shows that ricin may be 
transported by mechanisms similar to those used in the transport of cholera toxin and Shiga toxin from 
the cell surface to the trans-Golgi network. However, unlike cholera toxin, ricin trafficking from the 
trans-Golgi network to the ER remains independent of the KDEL motif. Interestingly, ricin can interact 
with calreticulin (which has a KDEL retention motif) in the Golgi network [172].  
Most proteolytically cleaved toxins enter the ER with the A and B subunits linked by a disulfide 
bond. The ricin B subunit hinders the A subunit catalytic activity, thus inactivating holotoxin activity 
against  free  ribosomes.  As  a  result,  cleavage  of  the  AB  subunits  is  necessary  for  ricin  mediated 
cytotoxicity [173,174]. The ER chaperone protein, disulfide isomerase (PDI), may be responsible for 
dissociating the A subunit from the B subunit, and may itself be reduced in the process by thioredoxin 
[175,176].  This  reaction  allows  free  RTA  subunits  to  interact  with  lipids,  inducing  membrane 
instability [177]. 
7.2. Immunological and Clinical Applications of Ricin  
Ricin is classically known for its strong ability to elicit an immune response. High titers of anti-ricin 
IgG antibodies were generated in mice challenged with sub-lethal doses of formalin-inactivated ricin 
toxoid [178–182]. Monoclonal and polyclonal anti-ricin antibodies have also been synthesized and 
were found to be protective against either the RTA or RTB subunits [179,183–187]. Vaccines against 
ricin are developed with caution, due to the possibility of generating antibodies that could potentially Toxins 2010, 2  
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enhance cytotoxicity [185,187,188]. While toxoid vaccines have proven to be protective in animals, 
applications in humans may present further concerns [178,189–192]. Nonetheless, ricin has recently 
found increasingly widespread use as a research tool for the study of ribosome inactivation and protein 
transport. Coupled to ligands, ricin conjugates have been used to target and destroy tumor cells or 
tumor vasculature in specific cancer therapeutics [193,194]. 
In contrast to the well established property of ricin toxin as a strong inducer of immunity, the RTB 
subunit has shown increased promise for use as an enhancer of immune tolerance. When genetically 
linked  to  the  N-terminus  of  insulin  in  E.  coli,  the  bacterial  synthesized  INS-RTB  fusion  protein 
enhanced immunological suppression of pancreatic islet inflammation (insulitis), which is critical for 
prevention of Type 1 diabetes onset [76]. One potential caveat is the presence of substantial numbers 
of cysteine residues in the INS-RTB fusion protein, six cysteine residues in insulin and nine in RTB, 
which may substantially reduce the capacity of the fusion protein to fold into its native configuration. 
To obtain a correctly folded INS-RTB fusion protein for immunomodulatory studies, a gene encoding 
the INS-CTB fusion protein was transferred into potato plants to produce the natively folded fusion 
protein [195]. Plant protein expression systems frequently synthesize recombinant proteins that contain 
post-translational modifications useful for human immunotherapy. 
To enhance subunit vaccine immune responses in the future, RTB fusion proteins may be used in 
combination, or sequentially, with other toxin B subunit-antigen or autoantigen fusion proteins. It is 
speculated  that  these  prime  boost  multi-component  immunization  strategies  will  safely  enhance  
pro-inflammatory  or  anti-inflammatory  responses towards  the antigen  or  autoantigen, respectively. 
Thus, development of safer and more effective B subunit based vaccines is a goal that is now receiving 
increased attention from the scientific community.  
8. Conclusions 
The goal of this review was to examine the structure and function of prominent AB toxins and the 
implications  of  their  properties  to  be  used  as  adjuvant  molecules  for  the  enhancement  of  subunit 
vaccine  efficacy.  It  has  long  been  known  that  most  subunit  vaccines  contain  individual  pathogen 
proteins, which have low inherent immunostimulatory properties. Thus, immunomodulatory molecules 
that can safely enhance vaccine-specific immunity are in increasing demand. Based on a growing 
awareness of their potential implications for subunit vaccine development, several issues remain to be 
addressed. These include clarification of the mechanisms underlying AB toxin immunomodulation and 
the  ability  to  find  response  to  challenges  regarding  the  safety  and  efficacy  of  AB  toxin  
subunit applications. 
The molecular mechanisms responsible for adjuvant mediated immune responses remain largely 
obscure.  Surprisingly,  AB  toxin  subunits  appear  to  elicit  seemingly  contradictory  effects.  This 
controversial  observation  further  complicates  the  current  understanding  of  how  adjuvants  may 
function. It is becoming increasingly apparent that the antigen or autoantigen, to which a toxin B 
subunit  is  fused,  may  determine  whether  the  toxin  B  subunit  serves  as  an  adjuvant  for  increased 
immunity or for enhanced tolerance.  
Recently, the application of less immunogenic toxin B subunits that are fused with antigens to 
generate strong immunogenic properties has become an area of intense research. Further, the fusion of Toxins 2010, 2  
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toxin B subunits with autoantigens, which stimulates, in general, immune tolerance against the linked 
autoantigen, has been found to exert a particularly useful effect in preventing the development of 
organ-specific  autoimmune  diseases  [37,196,197,198].  On  occasion,  fusion  of  toxin  B  subunits  to 
specific autoantigens, such as carcinoembryonic antigen (CEA) or prostate specific antigen (PSA), 
resulted in stimulation of protective inflammatory responses [72,199]. However, while this observation 
provides hope for effective protective and interventional therapy against these forms of cancer, our 
laboratory, as well as others, are currently working on the elucidation of early mechanisms underlying 
specific  immune  responses  with  adjuvant  fusion  proteins.  Identification  of  pathogen  receptors  on 
antigen presenting cells, such as dendritic cell TLR’s with their ability to bridge innate and adaptive 
immune  responses,  has  provided  a  unique  opportunity  for  identification  of  pathways  that  can  be 
targeted for development of non-toxic mucosal adjuvants.  
Unfortunately,  the  development  of  immunomodulatory  molecule  research  has  been  unduly 
inhibited, due to frequent challenges about regulating adjuvant safety and efficacy. Safety concerns 
may arise from the potential for adjuvant molecules to overstimulate the immune system, resulting in 
unwanted or chronic inflammatory responses. These conditions may lead to disturbed immunological 
homeostasis, resulting in the onset of allergy or autoimmunity. Hence, only a few immuno-modulated 
mucosal  vaccines  have  been  approved  for  human  application.  Further,  complications  have  been 
observed with the application of holotoxins, such as LT, in mucosal vaccination. Nasal administration 
of LT was linked to  a rare adverse reaction, the  appearance  of Bell’s palsy.  To circumvent such 
problems, new generations of altered LT mutant adjuvants, such as LTK63, a molecule with reduced 
ADP ribosylating activity, were constructed and engaged in human trials by Novartis Vaccines [200]. 
In addition, it was discovered that intranasal co-delivery of such mutant molecules, together with HIV 
or tuberculosis antigens, was also linked to transient nerve paralysis [201]. Thus, it follows that the 
route of delivery of the adjuvant molecule can also be an issue. Intranasal delivery as seen in the 
LTK63 human trials may not be the safest route of vaccine delivery, due to possible retrograde axonal 
transport  of  the  vaccine  after  neuronal  ganglioside  binding  [201].  Unsatisfactory  results  using  the 
holotoxin and mutants of the holotoxin has stimulated a change in research focus toward use of the 
non-toxic LTB subunit in an effort to avoid adjuvant induced toxicity. Alternatively, other mucosal 
routes, such as transdermal or sublingual delivery, may be safer and require further exploration. Thus, 
development of safer and more effective mucosal adjuvants for human vaccination remains a high 
priority. We hope that the many opportunities for improvement in vaccination strategies presented by 
members of this intriguing AB toxin family will encourage collaboration and the flow of information 
among excited researchers. 
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